272124-60-4Relevant academic research and scientific papers
A conjugate vaccine using enantiopure hapten imparts superior nicotine-binding capacity
Lockner, Jonathan W.,Lively, Jenny M.,Collins, Karen C.,Vendruscolo, Janaína C. M.,Azar, Marc R.,Janda, Kim D.
, p. 1005 - 1011 (2015)
A leading nicotine conjugate vaccine was only efficacious for one-third of clinical trial participants, likely due in part to its use of racemic nicotine hapten, (±)-3′-AmNic. Immunization of male Wistar rats with (+)-, (-)-, or (±)-3′-AmNicSucTT and subsequent antibody immunoassays suggest that a vaccine using enantiopure (-)-3′-AmNic hapten imparts superior capacity to bind (-)-nicotine. Future nicotine vaccine clinical candidates must incorporate this design consideration (i.e., hapten enantiopurity) in order to maximize efficacy.
ENANTIOPURE HAPTENS FOR NICOTINE VACCINE DEVELOPMENT
-
Page/Page column 3, (2015/12/08)
The invention provides chiral haptens (-)-3'-AmNic and (-)-N4N for use in generating antibodies in a patient specific for (-)-nicotine. The haptens can be conjugated to suitable carrier proteins and administered as an antigenic mixture, optionally comprising adjuvant(s), to a patient suffering from nicotine or tobacco addiction or habituation.
